Ankyra Therapeutics receives clearance in US and Canada to advance its anchored immunotherapy agent into clinical trials

Oct. 25, 2023

Ankyra Therapeutics Inc. has received approval of its IND application by the FDA and its clinical trial application (CTA) by Health Canada for its lead agent, ANK-101, a novel tumor-directed anchored immune medicine.

BioWorld Science Regulatory Cancer Immuno-oncology FDA Health Canada IND

Today's news in brief

BioWorld

BioWorld briefs for March 28, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for March 28, 2025

FDA says changes in Dexcom G6, G7 sensors constitute misbranding

BioWorld MedTech

The U.S. FDA’s March 4, 2025, warning letter to Dexcom Inc. is a well-detailed but heavily redacted document explaining the agency’s misgivings about procedures...

CMV history cited in DMD liver death on Sarepta’s Elevidys

BioWorld

Wall Street was weighing the gravity of the death from acute liver failure of a patient who was treated for Duchenne muscular dystrophy (DMD) with Sarepta...

UK government abolishes NHS England

BioWorld MedTech

In a move that surprised many across the health care sector, the U.K. government decided to scrap NHS England, the body which runs the national health service...